Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Operating activities
Net income	$ 19,099	$ 13,941
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	16,075	15,543
Deferred income taxes	(14,979)	5,913
Provision for doubtful accounts receivable	433	600
Gain on sale of interest in Fabrix Systems Ltd.		(1,086)
Realized gain on marketable securities	(331)	(543)
Interest in the equity of investments	(402)	379
Stock-based compensation	2,793	2,317
Change in assets and liabilities:
Restricted cash and cash equivalents	3,532	(14,657)
Trade accounts receivable	(18,883)	1,758
Prepaid expenses, other current assets and other assets	(6,065)	6,450
Trade accounts payable, accrued expenses, income taxes payable, other current liabilities and other liabilities	8,488	(14,907)
Customer deposits	(2,403)	17,028
Deferred revenue	(6,843)	3,097
Net cash provided by operating activities	514	35,833
Investing activities
Capital expenditures	(17,050)	(13,964)
Proceeds from sale of interest in Fabrix Systems Ltd.		4,769
Payment for acquisition, net of cash acquired	(1,827)
Cash used for investments	(8,527)	(1,850)
Proceeds from sale and redemption of investments		632
Purchases of marketable securities	(38,720)	(29,800)
Proceeds from maturities and sales of marketable securities	30,836	24,176
Net cash used in investing activities	(35,288)	(16,037)
Financing activities
Dividends paid	(13,155)	(12,983)
Distributions to noncontrolling interests	(1,139)	(1,545)
Sale of Class B common stock.	10,000
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc.	1,000
Proceeds from sale of member interests in CS Pharma Holdings, LLC.	1,250
Proceeds from exercise of stock options	835
Repayment of note payable		(6,353)
Repurchases of Class B common stock	(1,838)	(4,773)
Net cash used in financing activities	(3,047)	(25,654)
Effect of exchange rate changes on cash and cash equivalents	(264)	(3,368)
Net decrease in cash and cash equivalents	(38,085)	(9,226)
Cash and cash equivalents at beginning of period	109,537	110,361
Cash and cash equivalents at end of period	71,452	101,135
Supplemental schedule of non-cash investing and financing activities
Reclassification of liability for member interests in CS Pharma Holdings, LLC	$ 8,750